Skip to main content
ImmunoPrecise Antibodies Ltd. (IPA)
NASDAQ: IPA · Real-Time Price · USD
0.386
-0.017 (-4.22%)
Feb 21, 2025, 4:00 PM EST - Market closed

ImmunoPrecise Antibodies Revenue

ImmunoPrecise Antibodies had revenue of 6.13M CAD in the quarter ending October 31, 2024, a decrease of -0.41%. This brings the company's revenue in the last twelve months to 24.07M, up 6.36% year-over-year. In the fiscal year ending April 30, 2024, ImmunoPrecise Antibodies had annual revenue of 24.52M with 18.65% growth.

Revenue (ttm)
24.07M CAD
Revenue Growth
+6.36%
P/S Ratio
0.60
Revenue / Employee
238,307 CAD
Employees
101
Market Cap
12.95M USD

Revenue Chart

* This company reports financials in CAD.

History

Fiscal Year End Revenue Change Growth
Apr 30, 202424.52M3.85M18.65%
Apr 30, 202320.67M1.30M6.72%
Apr 30, 202219.36M1.45M8.11%
Apr 30, 202117.91M3.85M27.42%
Apr 30, 202014.06M3.13M28.66%
Apr 30, 2019 Pro Pro Pro
Apr 30, 2018 Pro Pro Pro
Apr 30, 2017 Pro Pro Pro
Apr 30, 2016 Pro Pro Pro
Apr 30, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 400.28B
Johnson & Johnson 88.82B
Merck & Co. 64.17B
AbbVie 56.33B
AstraZeneca 54.07B
Novartis AG 51.72B
Eli Lilly and Company 45.04B
Thermo Fisher Scientific 42.88B
Revenue Rankings

IPA News

More News